Bicycle Therapeutics to Present Key Zelenectide Pevedotin Data at SABCS 2024 and Share Program Updates
Bicycle Therapeutics plc (NASDAQ: BCYC), a company at the forefront of developing a novel therapeutic class based on its proprietary bicyclic peptide (Bicycle®) technology, will showcase significant new data at the 2024 San Antonio Breast Cancer Symposium (SABCS), scheduled for December 10–13 in San Antonio, Texas. The presentation will highlight the enhanced anti-tumor activity of zelenectide pevedotin monotherapy in patients with triple-negative breast cancer (TNBC) who exhibit NECTIN4 gene amplification.
Key Data Highlights
The abstract outlines the improved anti-tumor efficacy observed with zelenectide pevedotin as a monotherapy in TNBC patients with NECTIN4 gene amplification. This genetic marker has been identified as a key driver in certain cancers, making these results a significant advancement in targeting aggressive breast cancers that have limited treatment options.
In addition to the SABCS presentation, Bicycle Therapeutics will unveil topline results from ongoing trials:
- Combination Therapy Data: Zelenectide pevedotin combined with pembrolizumab in first-line treatment for cisplatin-ineligible metastatic urothelial cancer patients.
- Monotherapy Data: Results of zelenectide pevedotin in non-small cell lung cancer (NSCLC) patients with NECTIN4 gene amplification.
SABCS Presentation Details
The poster presentation will provide in-depth insights into the monotherapy’s performance, including anti-tumor activity and potential clinical implications for treating TNBC.
- Title: Enhanced anti-tumor activity of zelenectide pevedotin in triple-negative breast cancer (TNBC) patients with NECTIN4 gene amplification
- Session Number: 4
- Date and Time: Thursday, Dec. 12, from 5:30 p.m. to 7 p.m. CT
- Presentation Number: P4-10-21
- Lead Author: Dr. Niklas Klümper, University Hospital Bonn
Conference Call and Webcast
To provide further context and discuss these updates, Bicycle Therapeutics will host a conference call and webcast for analysts and investors:
- Date: Friday, Dec. 13, 2024
- Time: 7 a.m. CT
- Dial-In Information: +1-833-816-1408 (U.S.) or +1-412-317-0501 (international). Request to join the “Bicycle Therapeutics” call.
- Webcast Access: A live webcast and replay will be available in the Investor section of the company’s website at bicycletherapeutics.com.
About Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage biopharmaceutical company pioneering a new class of therapeutics built on its proprietary Bicycle® technology. Bicycle molecules are synthetic short peptides constrained by small-molecule scaffolds, creating two loops that stabilize their structure. This unique design allows for highly selective and potent target binding, opening new avenues for drug development, particularly in areas with limited treatment options.
The company’s pipeline includes:
- Zelenectide Pevedotin (formerly BT8009): A Bicycle® Toxin Conjugate (BTC®) targeting Nectin-4, a well-validated tumor antigen implicated in various cancers.
- BT5528: Another BTC targeting EphA2, a traditionally challenging therapeutic target.
- BT7480: A Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and CD137, aimed at stimulating immune responses within tumors.
Beyond oncology, the company is exploring applications of its technology in radiopharmaceuticals through its Bicycle Radionuclide Conjugates (BRC®) program and partnering efforts to address diseases in other therapeutic areas.
Advancing Precision Medicine
The data to be presented at SABCS underscores the versatility and therapeutic potential of the Bicycle platform. By focusing on Nectin-4, a biomarker strongly associated with tumor progression, Bicycle Therapeutics is advancing precision medicine for cancers like TNBC, NSCLC, and urothelial cancer. The promising results from these trials highlight zelenectide pevedotin’s potential to redefine treatment paradigms for these patient populations.
About the Company
Headquartered in Cambridge, UK, Bicycle Therapeutics operates with significant capabilities and leadership presence in Cambridge, Massachusetts. The company’s mission is to leverage its innovative technology to address unmet medical needs across oncology and beyond.
For more details, visit bicycletherapeutics.com.
